Abstract
The diaminoquinazoline series has good potency against Mycobacterium tuberculosis. Resistant isolates have mutations in Rv3161c, a putative dioxygenase. We carried out metabolite analysis on a wild-type strain and an Rv3161c mutant strain after exposure to a diaminoquinazoline. The parental compound was found in intracellular extracts from the mutant but not the wild type. A metabolite consistent with a monohydroxylated form was identified in the wild type. These data support the hypothesis that Rv3161c metabolizes diaminoquinazolines in M. tuberculosis.
| Original language | English |
|---|---|
| Article number | e01505-18 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 63 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 21 Dec 2018 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antitubercular
- Diaminoquinazoline
- Dioxygenases
- Monooxygenases
- Mycobacterium tuberculosis
- Prodrug
Fingerprint
Dive into the research topics of 'Activation of 2,4-Diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a Putative Dioxygenase'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver